The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Bupropion: pharmacology and therapeutic applications
Abstract
A total of 17 years after its introduction, bupropion remains a safe and effective antidepressant, suitable for first-line use. Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Common side effects are nervousness and insomnia. Nausea appears slightly less common than with the SSRI drugs and sexual dysfunction is probably the least of any antidepressant. Bupropion is relatively safe in overdose with seizures being the predominant concern. The mechanism of action of bupropion is still uncertain but may be related to inhibition of presynaptic dopamine and norepinephrine reuptake transporters. The activity of vesicular monoamine transporter-2, the transporter pumping dopamine, norepinephrine and serotonin from the cytosol into presynaptic vesicles, is increased by bupropion and may be a component of its mechanism of action. Bupropion is approved for use in major depression and seasonal affective disorder and has demonstrated comparable efficacy to other antidepressants in clinical trials. Bupropion is also useful in augmenting a partial response to selective serotonin reuptake inhibitor antidepressants, although bupropion should not be combined with monoamine oxidase inhibitors. It may be less likely to provoke mania than antidepressants with prominent serotonergic effects. Bupropion is effective in helping people quit tobacco smoking. Anecdotal reports indicate bupropion may lower inflammatory mediators such as tumor necrosis factor-alpha, may lower fatigue in cancer and may help reduce concentration problems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose
Isbister, G. K., Bowe, S. J., Dawson, A., & Whyte, I. M. (2004) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 435
Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Kupka, R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 419
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 408
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
The Relationship Between Antidepressant Medication Use and Rate of Suicide
Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.165 · Cited by 393
Goldberg, J. F., Burdick, K. E., & Endick, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.564 · Cited by 372
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Fryer, J. D., & Lukas, R. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37928-5 · Cited by 283
Klos, K. J., Bower, J. H., Josephs, K. A., Matsumoto, J. Y., & Ahlskog, J. E. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.06.005 · Cited by 283
Bertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Human CYP2B6: expression, inducibility and catalytic activities
Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., & de Waziers, I. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00004 · Cited by 265
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258
Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain
Semenchuk, M. R., Sherman, S., & Davis, B. (2001) · Neurology · doi:10.1212/wnl.57.9.1583 · Cited by 256
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 255
Cryan, J. F., O'Leary, O. F., Jin, S.-H., Friedland, J. C., Ouyang, M., Hirsch, B. R., Page, M. E., Dalvi, A., Thomas, S. A., & Lucki, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401080101 · Cited by 252
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study
Chun-Fai-Chan, B., Koren, G., Fayez, I., Kalra, S., Voyer-Lavigne, S., Boshier, A., Shakir, S., & Einarson, A. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.09.027 · Cited by 234
Clayton, A. H., Warnock, J. K., Kornstein, S. G., Pinkerton, R., Sheldon-Keller, A., & McGarvey, E. L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0110 · Cited by 222
VMAT-Mediated Changes in Quantal Size and Vesicular Volume
Colliver, T. L., Pyott, S. J., Achalabun, M., & Ewing, A. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-14-05276.2000 · Cited by 213
Cooper, B. R., Hester, T. J., & Maxwell, R. A. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32266-4 · Cited by 213
Treatment of bulimia with bupropion: a multicenter controlled trial.
Horne, R. L., Ferguson, J. M., Pope, H. G., Hudson, J. I., Lineberry, C. G., Ascher, J. A., & Cato, A. E. (1988) · PubMed · Cited by 212
Damaj, M. I., Carroll, F. I., Eaton, J. B., Navarro, H. A., Blough, B. E., Mirza, S., Lukas, R. J., & Martin, B. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001313 · Cited by 212
Antidepressants and Periodic Leg Movements of Sleep
Yang, C., White, D. P., & Winkelman, J. W. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.022 · Cited by 209
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain
Miksys, S. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00136-9 · Cited by 199
Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines
Cozzi, N. V., Sievert, M. K., Shulgin, A. T., Jacob, P., & Ruoho, A. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00538-5 · Cited by 194
Brustolim, D., Ribeiro-dos-Santos, R., Kast, R. E., Altschuler, E. L., & Soares, M. B. P. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2005.12.007 · Cited by 194
Self-citationHesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00002 · Cited by 193
Segraves, R. T., Clayton, A., Croft, H., Wolf, A., & Warnock, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125686.20338.c1 · Cited by 190
Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R., Shea, V., & Ferris, R. M. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.43 · Cited by 184
Horst, W. D., & Preskorn, S. H. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00222-5 · Cited by 182
Dunner, D. L., Zisook, S., Billow, A. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0705 · Cited by 180
Pharmacogenetic investigation of smoking cessation treatment
Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., Krishnan, S., Niaura, R., & Epstein, L. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00007 · Cited by 178
The Safety of Newer Antidepressants in Pregnancy and Breastfeeding
Gentile, S. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00005 · Cited by 177
Use of Bupropion in Combination with Serotonin Reuptake Inhibitors
Zisook, S., Rush, A. J., Haight, B. R., Clines, D. C., & Rockett, C. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.027 · Cited by 173
Release of dopamine via the human transporter.
Eshleman, A., Henningsen, R. A., Neve, K., & Janowsky, A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09929-8 · Cited by 168
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., De La Garza, R., Fong, T., Wallace, C. L., Li, S.-H., Elkashef, A., Chiang, N., & Kahn, R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 164
Lerman, C. E., Shields, P. G., Wileyto, E. P., Audrain, J. E., Hawk, L. W., Pinto, A., Kucharski, S., Krishnan, S. S., NIAURA, R. S., & Epstein, L. H. (2003) · Health Psychology · doi:10.1037/0278-6133.22.5.541 · Cited by 163
TURPEINEN, M., TOLONEN, A., UUSITALO, J., JALONEN, J., PELKONEN, O., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.010 · Cited by 163
Tønnesen, P., Tonstad, S., Hjalmarson, Å., Lebargy, F., van Spiegel, P. I., Hider, A., Sweet, R., & Townsend, J. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01185.x · Cited by 162
A 102-center prospective study of seizure in association with bupropion.
Johnston, J. A., Lineberry, C. G., Ascher, J. A., Davidson, J. R. T., Khayrallah, M. A., Feighner, J. P., & Stark, P. (1991) · PubMed · Cited by 151
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150
Pharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients
Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1204 · Cited by 149
Killen, J. D., Robinson, T. N., Ammerman, S., Hayward, C., Rogers, J., Stone, C., Samuels, D., Levin, S. K., Green, S., & Schatzberg, A. F. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.4.729 · Cited by 146
Clinical issues in long-term treatment with antidepressants.
Zajecka, J. M. (2000) · PubMed · Cited by 144
Inhibition of CYP2D6 Activity by Bupropion
Kotlyar, M., Brauer, L. H., Tracy, T. S., Hatsukami, D. K., Harris, J., Bronars, C. A., & Adson, D. E. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162805.46453.e3 · Cited by 144
Bupropion and amitriptyline in the treatment of depressed patients.
LADER, M. H. (1983) · PubMed · Cited by 142
Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment with Bupropion XL
Modell, J. G., Rosenthal, N. E., Harriett, A. E., Krishen, A., Asgharian, A., Foster, V. J., Metz, A. L., Rockett, C. B., & Wightman, D. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.021 · Cited by 139
Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
Hsyu, P., Singh, A. K., Giargiari, T. D., Dunn, J. A., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04361.x · Cited by 137
Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.05.001 · Cited by 131
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Dewey, S. L., Hitzemann, R., Gifford, A. N., & Pappas, N. R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37918-2 · Cited by 125
Bupropion overdose: A 3-year multi-center retrospective analysis
Spiller, H. A., Ramoska, E. A., Krenzelok, E. P., Sheen, S. R., Borys, D. J., Villalobos, D., Muir, S., & Easom, L. A. J. (1994) · The American Journal of Emergency Medicine · doi:10.1016/0735-6757(94)90195-3 · Cited by 125
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D., Christensen, B. K., & Houle, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1166-3 · Cited by 122
Apomorphine‐induced penile erections in Parkinson's disease
O’Sullivan, J. D., & Hughes, A. J. (1998) · Movement Disorders · doi:10.1002/mds.870130326 · Cited by 120
Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent
Soroko, F. E., Mehta, N. B., Maxwell, R. A., Ferris, R. M., & Schroeder, D. H. (1977) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1977.tb11460.x · Cited by 119
Dworkin, R. H., Katz, J., & Gitlin, M. J. (2005) · Neurology · doi:10.1212/wnl.65.12_suppl_4.s7 · Cited by 116
How does bupropion work as a smoking cessation aid?
Warner, C., & Shoaib, M. (2005) · Addiction Biology · doi:10.1080/13556210500222670 · Cited by 115
Moss, E. L., Simpson, J. S., Pelletier, G., & Forsyth, P. A. (2005) · Psycho-Oncology · doi:10.1002/pon.952 · Cited by 115
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Turpeinen, M., Nieminen, R. M., Juntunen, T., Taavitsainen, P., Raunio, H., & Pelkonen, O. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.626 · Cited by 108
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., & Lineberry, C. G. (1991) · PubMed · Cited by 107
Comparison of Bupropion and Trazodone for the Treatment of Major Depression
Weisler, R. H., Johnston, J., Lineberry, C. G., Samara, B., Branconnier, R. J., & Billow, A. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00004 · Cited by 107
Pesola, G. R., & Avasarala, J. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(01)00474-7 · Cited by 105
Findlay, J. W. A., Fleet, J. V. W., Smith, P., Butz, R. F., Hinton, M. L., Blum, M. R., & Schroeder, D. H. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637513 · Cited by 103
Intentional bupropion overdoses
Shepherd, G., Velez, L. I., & Keyes, D. C. (2004) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2004.02.017 · Cited by 97
Behavioral and biochemical investigations of bupropion metabolites
Bondarev, M. L., Bondareva, T. S., Young, R., & Glennon, R. A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02010-7 · Cited by 93
Dannon, P. N., Lowengrub, K., Musin, E., Gonopolski, Y., & Kotler, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186867.90289.ed · Cited by 92
Miller, D. K., Sumithran, S. P., & Dwoskin, L. P. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033852 · Cited by 90
Bupropion exposures: clinical manifestations and medical outcome
Belson, M. G., & Kelley, T. R. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(02)00522-x · Cited by 88
Cox, L. S., Patten, C. A., NIAURA, R. S., Decker, P. A., Rigotti, N. A., Sachs, D. P. L., Buist, A. S., & Hurt, R. D. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30423.x · Cited by 86
Johnston, J. A., Fiedler‐Kelly, J., Glover, E. D., Sachs, D. P. L., Grasela, T. H., & DeVeaugh-Geiss, J. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110042852 · Cited by 86
Bupropion Sustained Release Treatment Reduces Fatigue in Cancer Patients
Cullum, J., Wojciechowski, A. E., Pelletier, G., & Simpson, J. S. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900209 · Cited by 84
Safety profile of sustained-release bupropion in depression: Results of three clinical trials
Settle, E. C., Stahl, S. M., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88301-0 · Cited by 83
Ferris, R. M., & Beaman, O. J. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90198-3 · Cited by 82
Bupropion SR for the treatment of postpartum depression: a pilot study
Nonacs, R. M., Soares, C. N., Viguera, A. C., Pearson, K. H., Poitras, J. R., & Cohen, L. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005079 · Cited by 82
Bupropion for Smoking Cessation: A Randomized Trial
Simon, J. A., Duncan, C., Carmody, T. P., & Hudes, E. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1797 · Cited by 81
Effect of Bupropion on Depression Symptoms in a Smoking Cessation Clinical Trial.
Lerman, C. E., NIAURA, R. S., Collins, B. N., Wileyto, E. P., Audrain-McGovern, J. E., Pinto, A., Hawk, L. W., & Epstein, L. H. (2004) · Psychology of Addictive Behaviors · doi:10.1037/0893-164x.18.4.362 · Cited by 80
Golden, R. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260047006 · Cited by 78
Bupropion increases striatal vesicular monoamine transport
Rau, K. S., Birdsall, E., Hanson, J. E., Johnson‐Davis, K. L., Carroll, F. I., Wilkins, D. G., Gibb, J. W., Hanson, G. R., & Fleckenstein, A. E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.004 · Cited by 76
DeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Loraas, E. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0706 · Cited by 75
Bupropion: clinical assay for amphetamine-like abuse potential.
Griffith, J. D., Carranza, J., Griffith, C., & Miller, L. L. (1983) · PubMed · Cited by 75
Single‐Dose Pharmacokinetics of Bupropion in Adolescents: Effects of Smoking Status and Gender
Stewart, J. J., Berkel, H. J., Parish, R. C., Simar, M. R., Syed, A., Bocchini, J. A., Wilson, J. T., & Manno, J. E. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010564 · Cited by 74
Reimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80060-x · Cited by 72
Antidepressant Profile of Bupropion and three Metabolites in Mice
Martin, P., Massol, J., Colin, J. N., Lacomblez, L., & Puech, A. J. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014505 · Cited by 71
Bupropion in the management of apathy
Corcoran, C., Wong, M. L., & O’Keane, V. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104043284 · Cited by 69
Clinical pharmacology of bupropion and imipramine in elderly depressives.
Branconnier, R. J., Cole, J. O., Ghazvinian, S., Spera, K. F., Oxenkrug, G. F., & Bass, J. L. (1983) · PubMed · Cited by 66
Gartlehner, G., Hansen, R. A., Carey, T. S., Lohr, K. N., Gaynes, B. N., & Randolph, L. C. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00001 · Cited by 65
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Psychiatric and Sexual Disorders Induced by Apomorphine in Parkinsonʼs Disease
Courty, E., Durif, F., Zénut, M., Courty, P., & Lavarenne, J. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00005 · Cited by 64
Double-Blind Comparison of Doxepin Versus Bupropion in Outpatients with a Major Depressive Disorder
Feighner, J. P., HENDRICKSON, G. G., Miller, L. L., & Stern, W. C. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602000-00006 · Cited by 61
Myles, P. S., Leslie, K., Angliss, M., Mezzavia, P. M., & Lee, L. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03943.x · Cited by 61
Rush, A. J., Trivedi, M. H., Carmody, T. J., Donahue, R. M., Houser, T. L., Bolden-Watson, C., Batey, S. R., Ascher, J. A., & Metz, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00249-9 · Cited by 60
Remission of Crohn's disease on bupropion
Kast, R. E., & Altschuler, E. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.29467 · Cited by 58
Self-citationBechara, A. J., Bertolino, M. V., Casabé, A. R., & Fredotovich, N. M. (2004) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2004.04030.x · Cited by 56
Faucette, S. R., Hawke, R. L., Shord, S. S., LeCluyse, E. L., & Lindley, C. M. (2001) · PubMed · Cited by 56
Bupropion May Improve Restless Legs Syndrome
Kim, S., Shin, I., Kim, J., Yang, S., Shin, H., & Yoon, J. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000194706.61224.29 · Cited by 55
Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Waxmonsky, J. G. (2005) · PubMed · Cited by 53
Haggsträm, F. M., Chatkin, J. M., Sussenbach-Vaz, E., Cesari, D. H., Fam, C. F., & Fritscher, C. C. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.05.003 · Cited by 53
Crohn’s disease remission on bupropion
Kane, S. V., Altschuler, E. L., & Kast, R. E. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.02.004 · Cited by 52
Self-citationIntraventricular conduction delay after bupropion overdose
Curry, S. C., Kashani, J., LoVecchio, F., & Holubek, W. J. (2005) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2005.01.027 · Cited by 52
Antidepressant response and plasma concentrations of bupropion.
Preskorn, S. (1983) · PubMed · Cited by 52
Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking
Hatsukami, D. K., Rennard, S. I., Patel, M. K., Kotlyar, M., Malcolm, R. J., Nides, M. A., Dozier, G., Bars, M. P., & Jamerson, B. D. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.018 · Cited by 50
Why Isn't Bupropion the Most Frequently Prescribed Antidepressant?
Zimmerman, M. A., Posternak, M. A., Attiullah, N., Friedman, M. A., BOLAND, R. J., Baymiller, S., Berlowitz, S. L., Rahman, S., Uy, K. K., Singer, S., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0510 · Cited by 50
Johnson, R. A., Eshleman, A. J., Meyers, T., Neve, K. A., & Janowsky, A. J. (1998) · Synapse · Cited by 49
A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients.
Lf, F., Brodie, H. K. H., Garver, D., & Ww, Z. (1983) · PubMed · Cited by 49
A double-blind study of bupropion and placebo in depression
Feighner, J. P., Meredith, C. H., Stern, W. C., HENDRICKSON, G. G., & Miller, L. L. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.4.525 · Cited by 49
Bupropion sustained release: a therapeutic overview.
Davidson, J. R. T., & Connor, K. M. (1998) · PubMed · Cited by 49
Dong, J.-M., & Blier, P. (2001) · Psychopharmacology · doi:10.1007/s002130000665 · Cited by 48
Kast, R. E. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.006 · Cited by 48
Self-citationRecurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion
Wileyto, E. P., Patterson, F., NIAURA, R. S., Epstein, L. H., Brown, R. A., Audrain-McGovern, J. E., Hawk, L. W., & Lerman, C. E. (2005) · Nicotine & Tobacco Research · doi:10.1080/14622200500055673 · Cited by 48
Combined antidepressants: clinical experience
Rojo, E., Ros, S., Agüera, L., de la Gándara, J., & de Pedro, J. M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00677.x · Cited by 48
Review of placebo-controlled trials with bupropion.
Zung, W. W. K. (1983) · PubMed · Cited by 48
Truong, J. G., Newman, A. H., Hanson, G. R., & Fleckenstein, A. E. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.049 · Cited by 47
ECG Conduction Delays Associated with Massive Bupropion Overdose
Paris, P. A., & Saucier, J. R. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809028055 · Cited by 46
Güzey, C., Norström, Å., & Spigset, O. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00018 · Cited by 44
Adverse Effects Associated with Extra Doses of Bupropion
Shepherd, G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1378 · Cited by 43
A comparative study of bupropion and amitriptyline in depressed outpatients.
MENDELS, J., Amin, M. M., Chouinard, G., Cooper, A. J., Miles, J., Remick, R. A., Saxena, B., Secunda, S. K., & Singh, A. (1983) · PubMed · Cited by 43
Sertraline-Phenelzine Drug Interaction: A Serotonin Syndrome Reaction
Graber, M. A., Hoehns, T. B., & Perry, P. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800610 · Cited by 42
Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion
Musso, D. L., Mehta, N. B., Soroko, F. E., Ferris, R. M., Hollingsworth, E. B., & Kenney, B. T. (1993) · Chirality · doi:10.1002/chir.530050704 · Cited by 41
Bupropion-induced convulsions: Preclinical evaluation of antiepileptic drugs
Tutka, P., Mróz, T., Klucha, K., Piekarczyk, M., & Wielosz, M. (2005) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.01.006 · Cited by 40
Anorexia Nervosa in twins: case report and review.
Halaris, A. E., Stern, W. C., Fleet, J. V. W., & Reno, R. M. (1983) · PubMed · Cited by 40
Bupropion SR vs Placebo for Smoking Cessation in Health Care Professionals
Zellweger, J.-P., Boelcskei, P. L., Carrozzi, L., Sepper, R., Sweet, R., & Hider, A. (2005) · American Journal of Health Behavior · doi:10.5993/ajhb.29.3.5 · Cited by 39
Fatal interaction between tranylcypromine and imipramine
Otte, W., Birkenhäger, T. K., & van den Broek, W. W. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00090-7 · Cited by 38
Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
Yu, H., Rothman, R. B., Dersch, C. M., Partilla, J. S., & Rice, K. C. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00210-8 · Cited by 36
Kast, R. E., & Altschuler, E. M. (2005) · PubMed · Cited by 32
Self-citationLithium ions modulate the expression of VMAT2 in rat brain
Cordeiro, M. L., Gundersen, C. B., & Umbach, J. A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03284-5 · Cited by 32
Psychostimulants and Vesicle Trafficking: A Novel Mechanism and Therapeutic Implications
Hanson, G. R., Sandoval, V., Riddle, E. L., & Fleckenstein, A. E. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.019 · Cited by 31
Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: Four patient reports
Diamond, S., Pepper, B. J., Diamond, M. L., et al. (1998) · Neurology · doi:10.1212/wnl.51.1.274 · Cited by 28
Convulsant and anticonvulsant effects of bupropion in mice
Tutka, P., Barczyński, B., & Wielosz, M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.105 · Cited by 28
Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration
Truong, J. G., Hanson, G. R., & Fleckenstein, A. E. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.03.060 · Cited by 27
Little, J. T., Ketter, T. A., Mathé, A. A., Frye, M. A., Luckenbaugh, D. A., & Post, R. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00078-x · Cited by 26
The management of fatigue in depressed patients.
Marín, H., & Menza, M. A. (2005) · PubMed · Cited by 22
Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion
Kast, R. E., & Altschuler, E. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00172-7 · Cited by 20
Self-citationSerotonin Syndrome Secondary to Phenelzine‐Venlafaxine Interaction
Weiner, L. A., Smythe, M. A., & Cisek, J. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03869.x · Cited by 18
Nortriptyline toxicity secondary to interaction with bupropion sustained-release
Weintraub, D. A. (2001) · Depression and Anxiety · Cited by 16
Plasma nortriptyline and clinical response in depression
Murphy, G. E., Simons, A. D., & Wetzel, R. D. (1985) · Journal of Affective Disorders · doi:10.1016/0165-0327(85)90034-5 · Cited by 11
Bupropion and Chronic Aphthous Ulceration
Kast, R. E., & Altschuler, E. L. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.9.1167-a · Cited by 6
Self-citation
Cited by
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
“smoking cessation (389) that is a putative stimulator of the”
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Grippo, A. J., & Johnson, A. K. (2009) · Stress · doi:10.1080/10253890802046281 · Cited by 452
Psychiatric disorders in advanced cancer
Miovic, M., & Block, S. (2007) · Cancer · doi:10.1002/cncr.22980 · Cited by 376
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Metadata
- Authors
- Foley, K. F., DeSanty, K. P., & Kast, R. E.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2006-09
- Volume
- 6
- Issue
- 9
- Pages
- 1249-1265
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2099336264
- Cited by
- 352
- References
- 149
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.